Enanta Pharmaceuticals reported $44.73M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 311.34M 27.99M Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Immunic USD 31.55M 290K Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Insmed USD 596.57M 157.83M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
J&J USD 55.46B 562M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Novavax USD 329.84M 729K Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026